Skip to main content
Top
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Research article

A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients

Authors: Yuan Huang, Gong Cheng, Bianjiang Liu, Pengfei Shao, Chao Qin, Jie Li, Lixin Hua, Changjun Yin

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

The nomograms used for prostate cancer risk assessment in Western countries are not directly applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them developing this disease.

Methods

A total of 1104 patients who had undergone trans-rectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy were retrospectively evaluated in the first stage of the study. Age, prostate-specific antigen (PSA), the free/total PSA ratio (f/t), digital rectal examination (DRE) findings, the presence of a hypoechoic mass revealed using ultrasound, ultrasonic detection of microcalcifications, prostate volume (PV) and PSA density were considered as predictive factors. Multiple logistic regression analysis involving a backward elimination selection procedure was used to select independent predictors. We compared positive rates regarding 6-core and 12-core biopsy schemes at different risk levels. In the second stage of the study, 238 cases were evaluated using our nomogram. In higher risk patients, we employed a 6 + 1 core biopsy. Positive rates in the first and second stages of the study were compared.

Results

Age, the baseline median natural logarithm of PSA (Ln[PSA]), Ln(PV), f/t, rate of abnormal DRE findings and rate of hypoechoic masses detected using TRUS were the factors that were finally submitted into our nomogram. A significantly greater area under the receiver-operating characteristic curve was obtained for the nomogram than for PSA level alone (0.853 vs. 0.761). A cancer probability cutoff value of 0.5 suggested no significant difference between the 6-core and 12-core biopsy schemes at higher risk levels. In the second stage of the study we verified that in patients with a cancer probability cutoff value >0.5, a 6 + 1-core biopsy could be used without a reduction in the positive detection rate, and significantly reducing the number of biopsy cores required.

Conclusions

A nomogram based on data from Chinese males was developed to predict the positive detection rate, ratio of positive cores and Gleason score at each risk level. According to this nomogram, a reasonable biopsy strategy could be constituted to reduce the number of biopsy cores required in subjects at high risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995, 274: 1214-1220. 10.1001/jama.1995.03530150038031.CrossRefPubMed Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995, 274: 1214-1220. 10.1001/jama.1995.03530150038031.CrossRefPubMed
2.
go back to reference Loeb S, Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249: 30-39. 10.1016/j.canlet.2006.12.022.CrossRefPubMed Loeb S, Catalona WJ: Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249: 30-39. 10.1016/j.canlet.2006.12.022.CrossRefPubMed
3.
go back to reference Vickers AJ, Savage C, O’Brien MF, Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009, 27: 398-403.CrossRefPubMedPubMedCentral Vickers AJ, Savage C, O’Brien MF, Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009, 27: 398-403.CrossRefPubMedPubMedCentral
4.
go back to reference Schroder F, Kattan MW: The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008, 54: 274-290. 10.1016/j.eururo.2008.05.022.CrossRefPubMed Schroder F, Kattan MW: The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008, 54: 274-290. 10.1016/j.eururo.2008.05.022.CrossRefPubMed
5.
go back to reference Yoon DK, Park JY, Yoon S, Park MS, du Moon G, Lee JG, Schroder FH: Can the prostate risk calculator based on Western population be applied to Asian population?. Prostate. 2012, 72: 721-729. 10.1002/pros.21475.CrossRefPubMed Yoon DK, Park JY, Yoon S, Park MS, du Moon G, Lee JG, Schroder FH: Can the prostate risk calculator based on Western population be applied to Asian population?. Prostate. 2012, 72: 721-729. 10.1002/pros.21475.CrossRefPubMed
6.
go back to reference Cavadas V, Osório L, Sabell F, Teves F, Branco F, Silva-Ramos M: Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol. 2010, 58: 551-558. 10.1016/j.eururo.2010.06.023.CrossRefPubMed Cavadas V, Osório L, Sabell F, Teves F, Branco F, Silva-Ramos M: Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol. 2010, 58: 551-558. 10.1016/j.eururo.2010.06.023.CrossRefPubMed
7.
go back to reference Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW: External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort. Asian J Androl. 2012, 14: 738-744. 10.1038/aja.2012.28.CrossRefPubMedPubMedCentral Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW: External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort. Asian J Androl. 2012, 14: 738-744. 10.1038/aja.2012.28.CrossRefPubMedPubMedCentral
8.
go back to reference Hodge KK, McNeal JE, Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol. 1989, 142: 66-70.PubMed Hodge KK, McNeal JE, Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol. 1989, 142: 66-70.PubMed
9.
go back to reference Terris MK, Wallen EM, Stamey TA: Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int. 1997, 59: 239-242. 10.1159/000283071.CrossRefPubMed Terris MK, Wallen EM, Stamey TA: Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int. 1997, 59: 239-242. 10.1159/000283071.CrossRefPubMed
10.
go back to reference Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157: 199-202. 10.1016/S0022-5347(01)65322-9.CrossRefPubMed Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997, 157: 199-202. 10.1016/S0022-5347(01)65322-9.CrossRefPubMed
11.
go back to reference Chang JJ, Shinohara K, Bhargava V, Presti JC: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol. 1998, 160: 2111-2114. 10.1016/S0022-5347(01)62254-7.CrossRefPubMed Chang JJ, Shinohara K, Bhargava V, Presti JC: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol. 1998, 160: 2111-2114. 10.1016/S0022-5347(01)62254-7.CrossRefPubMed
12.
go back to reference Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000, 163: 152-157. 10.1016/S0022-5347(05)67993-1.CrossRefPubMed Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000, 163: 152-157. 10.1016/S0022-5347(05)67993-1.CrossRefPubMed
13.
go back to reference Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78: 313-317. 10.1159/000100834.CrossRefPubMed Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007, 78: 313-317. 10.1159/000100834.CrossRefPubMed
14.
go back to reference Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T: Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology. 2006, 68: 815-819. 10.1016/j.urology.2006.05.010.CrossRefPubMed Inahara M, Suzuki H, Kojima S, Komiya A, Fukasawa S, Imamoto T, Naya Y, Ichikawa T: Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology. 2006, 68: 815-819. 10.1016/j.urology.2006.05.010.CrossRefPubMed
15.
go back to reference Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010, 60: 70-98. 10.3322/caac.20066.CrossRefPubMed Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010, 60: 70-98. 10.3322/caac.20066.CrossRefPubMed
16.
go back to reference Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schroder FH, Roobol MJ: Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the rotterdam section of the european randomized study of screening for prostate cancer. Eur Urol. 2013, [Epub ahead of print] Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schroder FH, Roobol MJ: Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the rotterdam section of the european randomized study of screening for prostate cancer. Eur Urol. 2013, [Epub ahead of print]
17.
go back to reference Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360: 1310-1319. 10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360: 1310-1319. 10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral
18.
go back to reference Carlson GD, Calvanese CB, Partin AW: An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology. 1998, 52: 455-461. 10.1016/S0090-4295(98)00205-2.CrossRefPubMed Carlson GD, Calvanese CB, Partin AW: An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology. 1998, 52: 455-461. 10.1016/S0090-4295(98)00205-2.CrossRefPubMed
19.
go back to reference Eastham JA, May R, Robertson JL, Sartor O, Kattan MW: Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999, 54: 709-713. 10.1016/S0090-4295(99)00213-7.CrossRefPubMed Eastham JA, May R, Robertson JL, Sartor O, Kattan MW: Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999, 54: 709-713. 10.1016/S0090-4295(99)00213-7.CrossRefPubMed
20.
go back to reference Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW: Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology. 2001, 57: 1100-1104. 10.1016/S0090-4295(01)00980-3.CrossRefPubMed Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW: Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology. 2001, 57: 1100-1104. 10.1016/S0090-4295(01)00980-3.CrossRefPubMed
21.
go back to reference Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW: Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology. 1998, 52: 808-813. 10.1016/S0090-4295(98)00344-6.CrossRefPubMed Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW: Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology. 1998, 52: 808-813. 10.1016/S0090-4295(98)00344-6.CrossRefPubMed
22.
go back to reference Kim JW, Lee HY, Hong SJ, Chung BH: Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J. 2004, 45: 671-675.CrossRefPubMed Kim JW, Lee HY, Hong SJ, Chung BH: Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J. 2004, 45: 671-675.CrossRefPubMed
23.
go back to reference Tang P, Chen H, Uhlman M, Lin YR, Deng XR, Wang B, Yang WJ, Xie KJ: A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl. 2013, 15 (1): 129-133. 10.1038/aja.2012.111.CrossRefPubMed Tang P, Chen H, Uhlman M, Lin YR, Deng XR, Wang B, Yang WJ, Xie KJ: A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl. 2013, 15 (1): 129-133. 10.1038/aja.2012.111.CrossRefPubMed
Metadata
Title
A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients
Authors
Yuan Huang
Gong Cheng
Bianjiang Liu
Pengfei Shao
Chao Qin
Jie Li
Lixin Hua
Changjun Yin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-8

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue